



FOR IMMEDIATE RELEASE

Contact:

Samina Bari

Ikaria

(908) 238-6372

samina.bari@ikaria.com

IKARIA® APPOINTS CHIEF MEDICAL OFFICER

Clinton, NJ, June 8, 2010 – Ikaria, Inc. today announced that Geoffrey Nichol, M.D., has been appointed Chief Medical Officer. In this newly created role, Dr. Nichol will be responsible for activities related to late-stage drug development.

"We are delighted to welcome Geoff, who will leverage his extensive experience in driving our late-stage assets forward," commented Daniel Tassé, Chairman and CEO of Ikaria. "We believe he can help us achieve our vision of becoming a leader in critical care by driving the commercialization process of our two late-stage product candidates, as well as the FDA approval process for the additional indications we are pursuing for our marketed product INOMAX®."

Dr. Nichol, who has over 20 years of experience in the pharmaceutical industry, joins Ikaria from Medarex, Inc., where he was Senior Vice President of Product Development. Prior to his tenure at Medarex, Dr. Nichol held several leadership positions at Novartis Pharmaceuticals, and began his industry career at SmithKline Beecham Pharmaceuticals.

About Ikaria, Inc.

Ikaria, Inc. is a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to address the significant unmet needs of critically ill patients. The company's lead product is INOtherapy®, an all-inclusive offering of drug product, services and technologies. INOMAX® (nitric oxide) for inhalation, the drug included in the INOtherapy offering, is the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. INOtherapy also is marketed in Puerto Rico, Canada, Australia, Mexico and Japan. Ikaria acquired the North American and Australian rights to LUCASSIN® (terlipressin), a potential treatment for hepatorenal syndrome Type 1, as well as the exclusive worldwide license to IK-5001, a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. The company also has a number of investigational compounds in development. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. Please visit www.ikaria.com.

###